Biotech Values

[DewDiligence]

EQRx goes_public_via_revere-merger_with CMLTU SPAC:

https://www.businesswire.com/news/home/20210806005227/en/EQRx-to-Accelerate-Growth-with-1.8-Billion-Raise-through-Proposed-Combination-with-CM-Life-Sciences-III

EQRx is purpose-built, at scale, to develop and deliver innovative medicines to patients at radically lower prices through a late-stage and growing product pipeline across high-cost therapeutic categories and emerging partnerships with leading payers and healthcare providers.

EQRx is building a pipeline of innovative new drug candidates to address diseases like cancer and inflammatory conditions that are the top categories of drug spend today and in the future. By leveraging proven druggable targets and a focus on efficiency, together with building deep strategic partnerships with health systems and payers, EQRx anticipates a higher probability of regulatory success, a lower risk-adjusted cost of drug development and a more streamlined access model.

…EQRx’s growing pipeline of 10+ programs includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs. In addition, EQRx is further expanding its portfolio through drug engineering collaborations with leading drug discovery companies including Exscientia and AbCellera Biologics Inc.

Maybe. See #msg-153252951 for background info.

When the merger closes, the ticker symbol will change to ‘EQRX’.